Published in G Ital Dermatol Venereol on April 01, 2010
Novel, cysteine-modified chelation strategy for the incorporation of [M(I)(CO)(3)](+) (M = Re, (99m)Tc) in an α-MSH peptide. Bioconjug Chem (2012) 0.88
Clickable, hydrophilic ligand for fac-[M(I)(CO)3](+) (M = Re/(99m)Tc) applied in an S-functionalized α-MSH peptide. Bioconjug Chem (2014) 0.86
Improved synthesis and biological evaluation of chelator-modified α-MSH analogs prepared by copper-free click chemistry. Bioorg Med Chem Lett (2011) 0.82
Evaluation of (68)Ga- and (177)Lu-DOTA-PEG4-LLP2A for VLA-4-Targeted PET Imaging and Treatment of Metastatic Melanoma. Mol Pharm (2015) 0.82
Malignant melanoma and melanocortin 1 receptor. Biochemistry (Mosc) (2013) 0.81
Peptide-based imaging agents for cancer detection. Adv Drug Deliv Rev (2016) 0.81
Evaluation of novel 99mTc(I)-labeled homobivalent α-melanocyte-stimulating hormone analogs for melanocortin-1 receptor targeting. J Biol Inorg Chem (2012) 0.77
Evaluation of two (125)I-radiolabeled acridine derivatives for Auger-electron radionuclide therapy of melanoma. Invest New Drugs (2014) 0.75
PET and SPECT imaging of melanoma: the state of the art. Eur J Nucl Med Mol Imaging (2017) 0.75
Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg (1992) 9.97
Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol (2004) 5.49
Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med (2008) 4.71
The cloning of a family of genes that encode the melanocortin receptors. Science (1992) 4.64
Melanocyte biology and skin pigmentation. Nature (2007) 3.43
4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proc Natl Acad Sci U S A (1980) 2.80
Tumor therapy with targeted atomic nanogenerators. Science (2001) 2.48
An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin (2004) 2.18
Quantitative PET studies in pretreated melanoma patients: a comparison of 6-[18F]fluoro-L-dopa with 18F-FDG and (15)O-water using compartment and noncompartment analysis. J Nucl Med (2001) 2.04
Characterization of receptors for alpha-melanocyte-stimulating hormone on human melanoma cells. Cancer Res (1989) 2.03
The melanocortin receptors: agonists, antagonists, and the hormonal control of pigmentation. Recent Prog Horm Res (1996) 1.94
Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma. J Nucl Med (2000) 1.93
99mTc- and 111In-labeled alpha-melanocyte-stimulating hormone peptides as imaging probes for primary and pulmonary metastatic melanoma detection. J Nucl Med (2007) 1.81
Effect of alpha- and betamelanocyte stimulating hormones on the skin colour of man. Nature (1961) 1.80
64Cu-labeled alpha-melanocyte-stimulating hormone analog for microPET imaging of melanocortin 1 receptor expression. Bioconjug Chem (2007) 1.79
A gallium-labeled DOTA-alpha-melanocyte- stimulating hormone analog for PET imaging of melanoma metastases. J Nucl Med (2004) 1.76
Melanoma-targeting properties of (99m)technetium-labeled cyclic alpha-melanocyte-stimulating hormone peptide analogues. Cancer Res (2000) 1.73
Trifunctional somatostatin-based derivatives designed for targeted radiotherapy using auger electron emitters. J Nucl Med (2005) 1.64
Evaluation of the human melanoma targeting properties of radiolabeled alpha-melanocyte stimulating hormone peptide analogues. Bioconjug Chem (2003) 1.58
A novel DOTA-alpha-melanocyte-stimulating hormone analog for metastatic melanoma diagnosis. J Nucl Med (2002) 1.57
Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides. Adv Drug Deliv Rev (2008) 1.55
Potent and prolonged acting cyclic lactam analogues of alpha-melanotropin: design based on molecular dynamics. J Med Chem (1989) 1.54
[177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer (2001) 1.53
Vehicles, chelators, and radionuclides: choosing the "building blocks" of an effective therapeutic radioimmunoconjugate. Bioconjug Chem (1997) 1.52
Melanoma therapy via peptide-targeted {alpha}-radiation. Clin Cancer Res (2005) 1.52
Imaging of melanoma using 64Cu- and 86Y-DOTA-ReCCMSH(Arg11), a cyclized peptide analogue of alpha-MSH. J Med Chem (2005) 1.49
111In-labeled lactam bridge-cyclized alpha-melanocyte stimulating hormone peptide analogues for melanoma imaging. Bioconjug Chem (2008) 1.48
Synthesis and biologic evaluation of 64Cu-labeled rhenium-cyclized alpha-MSH peptide analog using a cross-bridged cyclam chelator. J Nucl Med (2007) 1.42
Therapeutic efficacy of a 188Re-labeled alpha-melanocyte-stimulating hormone peptide analog in murine and human melanoma-bearing mouse models. J Nucl Med (2005) 1.41
Design and characterization of alpha-melanotropin peptide analogs cyclized through rhenium and technetium metal coordination. Proc Natl Acad Sci U S A (1998) 1.39
In vivo evaluation of 188Re-labeled alpha-melanocyte stimulating hormone peptide analogs for melanoma therapy. Int J Cancer (2002) 1.37
Metastatic melanoma imaging with an (111)In-labeled lactam bridge-cyclized alpha-melanocyte-stimulating hormone peptide. Nucl Med Biol (2009) 1.36
Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet (1998) 1.34
Evaluation of an (111)In-DOTA-rhenium cyclized alpha-MSH analog: a novel cyclic-peptide analog with improved tumor-targeting properties. J Nucl Med (2001) 1.33
Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med (2002) 1.33
Melanocortin receptors: their functions and regulation by physiological agonists and antagonists. Cell Mol Life Sci (2001) 1.32
Radioguided sentinel lymph node biopsy in malignant cutaneous melanoma. J Nucl Med (2002) 1.32
Receptor targeting for tumor localisation and therapy with radiopeptides. Curr Med Chem (2000) 1.23
Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. J Urol (1998) 1.23
203Pb-labeled alpha-melanocyte-stimulating hormone peptide as an imaging probe for melanoma detection. J Nucl Med (2008) 1.22
Modification of the structure of a metallopeptide: synthesis and biological evaluation of (111)In-labeled DOTA-conjugated rhenium-cyclized alpha-MSH analogues. J Med Chem (2002) 1.21
Therapeutic radionuclides: production and decay property considerations. J Nucl Med (1991) 1.19
Is 18F-FDG PET more accurate than standard diagnostic procedures in the detection of suspected recurrent melanoma? J Nucl Med (2004) 1.19
Small-animal PET of melanocortin 1 receptor expression using a 18F-labeled alpha-melanocyte-stimulating hormone analog. J Nucl Med (2007) 1.16
The development of the alpha-particle emitting radionuclides 212Bi and 213Bi, and their decay chain related radionuclides, for therapeutic applications. Chem Rev (2001) 1.14
Tumor-targeting properties of 90Y- and 177Lu-labeled alpha-melanocyte stimulating hormone peptide analogues in a murine melanoma model. Nucl Med Biol (2005) 1.12
Primary staging and follow-up in melanoma patients--monocenter evaluation of methods, costs and patient survival. Br J Cancer (2002) 1.11
A (99m)Tc(CO)(3)-labeled pyrazolyl-alpha-melanocyte-stimulating hormone analog conjugate for melanoma targeting. Nucl Med Biol (2007) 1.10
DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med (1997) 1.09
Evaluation of a novel Arg-Gly-Asp-conjugated α-melanocyte stimulating hormone hybrid peptide for potential melanoma therapy. Bioconjug Chem (2009) 1.08
Endocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapy. Best Pract Res Clin Gastroenterol (2005) 1.08
Systematic review of the diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography in melanoma patients. Cancer (2001) 1.05
Radioiodination of rhenium cyclized alpha-melanocyte-stimulating hormone resulting in enhanced radioactivity localization and retention in melanoma. Cancer Res (2004) 1.04
In vivo evaluation of 99mTc/188Re-labeled linear alpha-melanocyte stimulating hormone analogs for specific melanoma targeting. Nucl Med Biol (1999) 1.03
Melanoma targeting with alpha-melanocyte stimulating hormone analogs labeled with fac-[99mTc(CO)3]+: effect of cyclization on tumor-seeking properties. J Biol Inorg Chem (2008) 1.02
Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma. Cancer (2005) 1.02
Melanin-targeted preclinical PET imaging of melanoma metastasis. J Nucl Med (2009) 1.02
Targeted alpha-therapy: past, present, future? Dalton Trans (2007) 1.01
Truncation studies of alpha-melanotropin peptides identify tripeptide analogues exhibiting prolonged agonist bioactivity. Peptides (1996) 1.00
Therapeutic efficacy of a 177Lu-labeled DOTA conjugated alpha-melanocyte-stimulating hormone peptide in a murine melanoma-bearing mouse model. Cancer Biother Radiopharm (2007) 1.00
Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma. J Clin Oncol (2001) 0.99
Melanotropin receptors demonstrated in situ in human melanoma. J Clin Invest (1990) 0.99
Gallium-68-labeled DOTA-rhenium-cyclized alpha-melanocyte-stimulating hormone analog for imaging of malignant melanoma. Nucl Med Biol (2007) 0.97
Cyclic melanotropins. 9. 7-D-Phenylalanine analogues of the active-site sequence. J Med Chem (1985) 0.96
2-Deoxy-2-[F-18]fluoro-D-glucose positron emission tomography/computed tomography in the management of melanoma. Mol Imaging Biol (2007) 0.95
PET of malignant melanoma using 18F-labeled metallopeptides. J Nucl Med (2009) 0.93
Radioreceptor assay for alpha-MSH using mouse B16 melanoma cells+. J Recept Res (1988) 0.93
The cytotoxicity and microdosimetry of astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells in vitro. Radiat Res (1998) 0.93
Fluorine-18-labeled [Nle4,D-Phe7]-alpha-MSH, an alpha-melanocyte stimulating hormone analogue. Nucl Med Biol (1997) 0.92
Enhanced binding and inertness to dehalogenation of alpha-melanotropic peptides labeled using N-succinimidyl 3-iodobenzoate. Bioconjug Chem (1997) 0.90
Fluor-18-fluorodeoxyglucose positron emission tomography (FDG-PET) in malignant melanoma. Diagnostic comparison with conventional imaging methods. Acta Radiol (2000) 0.90
Development of high-specific-activity (68)Ga-labeled DOTA-rhenium-cyclized alpha-MSH peptide analog to target MC1 receptors overexpressed by melanoma tumors. Nucl Med Biol (2009) 0.88
Design, synthesis, and conformation of superpotent and prolonged acting melanotropins. Ann N Y Acad Sci (1993) 0.88
Radiometal targeted tumor diagnosis and therapy with peptide hormones. Curr Pharm Des (2008) 0.87
Synthesis and characterization of rhenium-complexed alpha-melanotropin analogs. Bioconjug Chem (1997) 0.86
Staging of regional lymph nodes in melanoma patients by means of 99mTc-MIBI scintigraphy. J Nucl Med (2003) 0.86
Increased cell death after therapy with an Arg-Gly-Asp-linked somatostatin analog. J Nucl Med (2004) 0.85
Radionuclide therapy revisited. Eur J Nucl Med (1991) 0.84
Radioimaging of melanoma using 99mTc-labeled Fab fragment reactive with a high molecular weight melanoma antigen. Cancer Res (1990) 0.83
Clinical applications of FDG-PET in oncology. Acta Med Austriaca (2002) 0.83
Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers. Arch Dermatol (2004) 0.82
Synthesis and structure-function studies of melanocyte stimulating hormone analogues modified in the 2 and 4(7) positions: comparison of activities on frog skin melanophores and melanoma adenylate cyclase. J Med Chem (1980) 0.82
A chelating derivative of alpha-melanocyte stimulating hormone as a potential imaging agent for malignant melanoma. Br J Cancer (1990) 0.82
Scintigraphic detection of melanoma metastases with a radiolabeled benzamide ([iodine-123]-(S)-IBZM). J Nucl Med (1994) 0.81
The use of a chelating derivative of alpha melanocyte stimulating hormone for the clinical imaging of malignant melanoma. Br J Radiol (1992) 0.80
Biologically active monoiodinated alpha-MSH derivatives for receptor binding studies using human melanoma cells. J Recept Res (1991) 0.80
Successful imaging of malignant melanoma with technetium-99m-labeled monoclonal antibodies. J Nucl Med (1989) 0.80
Radiolabeled alpha-melanocyte-stimulating hormone analogs for receptor-mediated targeting of melanoma: from tritium to indium. J Mol Recognit (2003) 0.80
Benzamides as melanotropic carriers for radioisotopes, metals, cytotoxic agents and as enzyme inhibitors. Curr Med Chem (2009) 0.79
Routine positron emission tomography and positron emission tomography/computed tomography in melanoma staging with positive sentinel node biopsy is of limited benefit. Melanoma Res (2008) 0.78
Binding and internalization of the melanocyte stimulating hormone receptor ligand [Nle4, D-Phe7] alpha-MSH in B16 melanoma cells. Int J Biochem Cell Biol (1996) 0.77
Alpha-melanocyte stimulating hormone message and inhibitory sequences: comparative structure-activity studies on melanocytes. Peptides (1990) 0.77
Pre- and postnatal ontogeny of [125I]Nle4,D-Phe7-alpha-MSH binding sites in rat brain. Ann N Y Acad Sci (1993) 0.76
Synthesis of tritium labeled Ac-[Nle4, D-Phe7]-alpha-MSH4-11-NH2: a superpotent melanotropin with prolonged biological activity. Life Sci (1984) 0.76
Review of evidence-based support for pretreatment imaging in melanoma. J Natl Compr Canc Netw (2009) 0.76
Preparation of tritiated alpha-melanotropin with high specific radioactivity. Int J Pept Protein Res (1981) 0.76
A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell (2000) 17.61
Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet (2000) 8.58
Prevalence of specific language impairment in kindergarten children. J Speech Lang Hear Res (1997) 6.37
Histone-like TAFs within the PCAF histone acetylase complex. Cell (1998) 5.26
Negative regulation of Gcn4 and Msn2 transcription factors by Srb10 cyclin-dependent kinase. Genes Dev (2001) 4.91
Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3. Science (2000) 4.57
The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature (1998) 4.47
Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses. Blood (1998) 4.07
Crystal structure of four-stranded Oxytricha telomeric DNA. Nature (1992) 3.96
Aromatic hydrogen bond in sequence-specific protein DNA recognition. Nat Struct Biol (1996) 3.91
Effectiveness of community health workers in the care of persons with diabetes. Diabet Med (2006) 3.66
PKD1 interacts with PKD2 through a probable coiled-coil domain. Nat Genet (1997) 3.58
A presynaptic inositol-5-phosphatase. Nature (1996) 3.54
Identity between TRAP and SMCC complexes indicates novel pathways for the function of nuclear receptors and diverse mammalian activators. Mol Cell (1999) 3.47
Concerted dephosphorylation of the transcription factor NFAT1 induces a conformational switch that regulates transcriptional activity. Mol Cell (2000) 3.44
Phosphorylation of the AMPA receptor subunit GluR2 differentially regulates its interaction with PDZ domain-containing proteins. J Neurosci (2000) 3.44
State estimates of Medicaid expenditures attributable to cigarette smoking, fiscal year 1993. Public Health Rep (1998) 3.41
Three-dimensional structure of an evolutionarily conserved N-terminal domain of syntaxin 1A. Cell (1998) 3.40
Complications of radiofrequency coagulation of liver tumours. Br J Surg (2002) 3.39
Clustering of AMPA receptors by the synaptic PDZ domain-containing protein PICK1. Neuron (1999) 3.33
Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Oncogene (1999) 3.23
A herpesvirus of rhesus monkeys related to the human Kaposi's sarcoma-associated herpesvirus. J Virol (1997) 3.10
Real time detection of DNA.RNA hybridization in living cells. Proc Natl Acad Sci U S A (1998) 3.10
Mutations in the laminin alpha 2-chain gene (LAMA2) cause merosin-deficient congenital muscular dystrophy. Nat Genet (1995) 3.05
Timetables of neurogenesis in the human brain based on experimentally determined patterns in the rat. Neurotoxicology (1993) 3.00
Histone chaperone Asf1 is required for histone H3 lysine 56 acetylation, a modification associated with S phase in mitosis and meiosis. Proc Natl Acad Sci U S A (2006) 2.98
Human magnetic resonance imaging at 8 T. NMR Biomed (1998) 2.96
ORegAnno: an open access database and curation system for literature-derived promoters, transcription factor binding sites and regulatory variation. Bioinformatics (2006) 2.93
Identification of a translation initiation factor 3 (eIF3) core complex, conserved in yeast and mammals, that interacts with eIF5. Mol Cell Biol (1998) 2.91
Therapeutic benefit of intracerebral transplantation of bone marrow stromal cells after cerebral ischemia in rats. J Neurol Sci (2001) 2.84
Basal cell carcinomas in mice overexpressing Gli2 in skin. Nat Genet (2000) 2.82
cisRED: a database system for genome-scale computational discovery of regulatory elements. Nucleic Acids Res (2006) 2.75
A novel human SRB/MED-containing cofactor complex, SMCC, involved in transcription regulation. Mol Cell (1999) 2.71
An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature (1996) 2.71
New variants of a method of MRI scale standardization. IEEE Trans Med Imaging (2000) 2.69
Biosynthesis of the ansamycin antibiotic rifamycin: deductions from the molecular analysis of the rif biosynthetic gene cluster of Amycolatopsis mediterranei S699. Chem Biol (1998) 2.64
Targeted disruption of mouse Yin Yang 1 transcription factor results in peri-implantation lethality. Mol Cell Biol (1999) 2.61
Postsynaptic membrane fusion and long-term potentiation. Science (1998) 2.59
Role for a phage promoter in Shiga toxin 2 expression from a pathogenic Escherichia coli strain. J Bacteriol (2001) 2.59
Complete genome sequence of the shrimp white spot bacilliform virus. J Virol (2001) 2.58
Type I interferon-mediated stimulation of T cells by CpG DNA. J Exp Med (1998) 2.58
Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int J Epidemiol (2003) 2.57
A system for the diagnosis of specific language impairment in kindergarten children. J Speech Hear Res (1996) 2.52
The neuronal Rho-GEF Kalirin-7 interacts with PDZ domain-containing proteins and regulates dendritic morphogenesis. Neuron (2001) 2.52
Messenger plasticity in primary sensory neurons following axotomy and its functional implications. Trends Neurosci (1994) 2.44
Rett syndrome and beyond: recurrent spontaneous and familial MECP2 mutations at CpG hotspots. Am J Hum Genet (1999) 2.42
Large-scale psychological differences within China explained by rice versus wheat agriculture. Science (2014) 2.42
Structure of the haemagglutinin-esterase-fusion glycoprotein of influenza C virus. Nature (1998) 2.41
Regulation of morphological postsynaptic silent synapses in developing hippocampal neurons. Nat Neurosci (1999) 2.40
Autophosphorylation in the activation loop is required for full kinase activity in vivo of human and yeast eukaryotic initiation factor 2alpha kinases PKR and GCN2. Mol Cell Biol (1998) 2.39
The effects of diabetes on the risks of major cardiovascular diseases and death in the Asia-Pacific region. Diabetes Care (2003) 2.36
Ca2+ binding to synaptotagmin: how many Ca2+ ions bind to the tip of a C2-domain? EMBO J (1998) 2.31
Long-term non-pharmacological weight loss interventions for adults with prediabetes. Cochrane Database Syst Rev (2005) 2.26
Structural basis for co-stimulation by the human CTLA-4/B7-2 complex. Nature (2001) 2.21
Weakly acidic reflux in patients with chronic unexplained cough during 24 hour pressure, pH, and impedance monitoring. Gut (2005) 2.20
Multivariate matching and bias reduction in the surgical outcomes study. Med Care (2001) 2.19
State estimates of total medical expenditures attributable to cigarette smoking, 1993. Public Health Rep (1998) 2.18
Long-term non-pharmacologic weight loss interventions for adults with type 2 diabetes. Cochrane Database Syst Rev (2005) 2.17
In vivo transduction with shiga toxin 1-encoding phage. Infect Immun (1998) 2.16
PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats. J Control Release (2001) 2.15
Components of the Arabidopsis C-repeat/dehydration-responsive element binding factor cold-response pathway are conserved in Brassica napus and other plant species. Plant Physiol (2001) 2.14
Outdoor activity and myopia in Singapore teenage children. Br J Ophthalmol (2009) 2.13
Mouse suppressor of fused is a negative regulator of sonic hedgehog signaling and alters the subcellular distribution of Gli1. Curr Biol (1999) 2.12
PU.1 inhibits GATA-1 function and erythroid differentiation by blocking GATA-1 DNA binding. Blood (2000) 2.12
Std1 and Mth1 proteins interact with the glucose sensors to control glucose-regulated gene expression in Saccharomyces cerevisiae. Mol Cell Biol (1999) 2.11
Identification of the activating region of catabolite gene activator protein (CAP): isolation and characterization of mutants of CAP specifically defective in transcription activation. Proc Natl Acad Sci U S A (1993) 2.08
PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice. Kidney Int (2006) 2.05
Terahertz magnetic response from artificial materials. Science (2004) 2.05
The roaming atom: straying from the reaction path in formaldehyde decomposition. Science (2004) 2.02
The challenges of genome sequence annotation or "the devil is in the details". Nat Biotechnol (1997) 2.01
Novel organizational features, captured cellular genes, and strain variability within the genome of KSHV/HHV8. J Natl Cancer Inst Monogr (1998) 2.01
Associations of IL6 polymorphisms with lung function decline and COPD. Thorax (2009) 2.00
Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome. J Invest Dermatol (1998) 2.00
Severe diffuse non-scarring hair loss in systemic lupus erythematosus - clinical and histopathological analysis of four cases. J Eur Acad Dermatol Venereol (2011) 1.99
Colour tuning in human visual cortex measured with functional magnetic resonance imaging. Nature (1997) 1.98
Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Res (2000) 1.98
Genotyping of Toxoplasma gondii by multilocus PCR-RFLP markers: a high resolution and simple method for identification of parasites. Int J Parasitol (2006) 1.97
Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res (2000) 1.96
Prevalence of Staphylococcus aureus carrying Panton-Valentine leukocidin genes among isolates from hospitalised patients in China. Clin Microbiol Infect (2008) 1.95
Molecular cloning and expression of a gene encoding Cryptosporidium parvum glycoproteins gp40 and gp15. Infect Immun (2000) 1.94
Mechanisms of CAS substrate domain tyrosine phosphorylation by FAK and Src. Mol Cell Biol (2001) 1.91
Architecture of a K+ channel inner pore revealed by stoichiometric covalent modification. Neuron (1999) 1.90
The gene for nucleoside diphosphate kinase functions as a mutator gene in Escherichia coli. J Mol Biol (1995) 1.90
An interocular comparison of the multifocal VEP: a possible technique for detecting local damage to the optic nerve. Invest Ophthalmol Vis Sci (2000) 1.88
A precision measurement of the mass of the top quark. Nature (2004) 1.87
Regulation of Pax6 expression is conserved between mice and flies. Development (1999) 1.87
Reconfigurable terahertz metamaterials. Phys Rev Lett (2009) 1.86
Research gap in cardiovascular disease in developing countries. Lancet (2003) 1.86
Nonword repetition performance in school-age children with and without language impairment. J Speech Lang Hear Res (2000) 1.86
Differential display using one-base anchored oligo-dT primers. Nucleic Acids Res (1994) 1.85
Focal adhesion kinase tyrosine-861 is a major site of phosphorylation by Src. Biochem Biophys Res Commun (1996) 1.84
Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver. Proc Natl Acad Sci U S A (2001) 1.84
Mutations of the PATCHED gene in several types of sporadic extracutaneous tumors. Cancer Res (1997) 1.83
Trans-activation of the mouse cartilage-derived retinoic acid-sensitive protein gene by Sox9. J Bone Miner Res (1999) 1.82
Structure of human DNMT2, an enigmatic DNA methyltransferase homolog that displays denaturant-resistant binding to DNA. Nucleic Acids Res (2001) 1.81
The association of reading disability, behavioral disorders, and language impairment among second-grade children. J Child Psychol Psychiatry (2000) 1.81
The effect of prolonged and exclusive breast-feeding on dental caries in early school-age children. New evidence from a large randomized trial. Caries Res (2007) 1.78
From naive to memory T cells. Immunol Rev (1996) 1.76